Related Experiment Videos
Acetazolamide in dominant cystoid macular dystrophy. A pilot study
A Pinckers1, J R Cruysberg, H Kremer
1Institute of Ophthalmology, University of Nijmegen, The Netherlands.
Ophthalmic Paediatrics and Genetics
|June 1, 1993
Summary
Acetazolamide treatment did not improve visual acuity in patients with dominant cystoid macular dystrophy. This study suggests oral acetazolamide is ineffective for treating cystoid macular edema in this condition.
Area of Science:
- Ophthalmology
- Medical Genetics
Background:
- Autosomal dominant cystoid macular dystrophy is a genetic condition causing low visual acuity.
- Cystoid macular edema is a common feature of this dystrophy.
Purpose of the Study:
- To evaluate the efficacy of acetazolamide in treating dominant cystoid macular dystrophy.
Main Methods:
- Eight patients with dominant cystoid macular dystrophy received daily oral acetazolamide (250 mg) for 2 to 17 months.
Main Results:
- None of the eight patients experienced a visual acuity improvement exceeding 0.1.
- Electroretinography showed a normal b-wave/a-wave ratio.
Conclusions:
- Oral acetazolamide (250 mg) appears ineffective for treating cystoid macular edema in dominant cystoid macular dystrophy.
- The underlying pathology of dominant cystoid macular dystrophy remains unclear.